The purpose of the concordance validation was to evaluate if the same high quality of data could be obtained at Olink labs as at Olink Analysis Service labs, to ensure they can provide stable and accurate results that fulfill the Olink QC acceptance criteria. The results in the concordance tech note showed that Sequanta could produce the same high quality data as the Olink Analysis Service lab.
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.